

2021-03-01

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference (MCID)

Masoli, M

<http://hdl.handle.net/10026.1/16966>

10.1183/13993003.00300-2021

European Respiratory Journal

European Respiratory Society

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

The Severe Asthma Questionnaire: Sensitivity to change and minimum important clinical difference (MCID)

Authors

Matthew Masoli¹, Joseph W. Lanario², Michael E. Hyland^{2,3}, Andrew Menzies-Gow⁴, Adel H Mansur⁵, David Allen⁶, James W. Dodd⁷, Gemma Hayes⁸, Jose M Valderas⁹, Sally E Lamb⁹, Rupert C. Jones²

1. Royal Devon and Exeter Hospital, Exeter, UK, University of Exeter
2. Faculty of Health, University of Plymouth, Plymouth, UK
3. Plymouth Marjon University, Plymouth, UK
4. Royal Brompton Hospital, London, UK
5. Heartlands Hospital, University Hospitals Birmingham and University of Birmingham, Birmingham, UK
6. School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
7. Academic Respiratory Unit, University of Bristol, Southmead Hospital, North Bristol Hospital Trust, Bristol, UK
8. University Hospitals Plymouth NHS Trust, Plymouth, UK
9. College of Medicine and Health, University of Exeter, Exeter, UK

Corresponding author: Matthew Masoli

Accepted February 8, 2021

To the editor:

The Severe Asthma Questionnaire (SAQ) is a validated measure of the health related quality of life of people living with severe asthma [1]. The minimum important clinical difference (MCID) of the SAQ has not been calculated. The MCID is useful for representing clinical as opposed to statistical significance. There are two main ways of calculating the MCID. Distribution methods define the MCID in terms of the relationship between the distribution of scores and mean change score. These methods are purely statistical and the relationship and formulae that constitute the MCID is determined by convention. By contrast, the anchor method [2] defines the MCID in terms of an independent anchor or criterion. When the anchor is the patient's perception of a just noticeable difference in their condition, then the anchor method has two advantages over the distribution method. First, the MCID is defined by a criterion and therefore has criterion validity rather than being only a convention. Second, the MCID is defined in terms of the patient's perception of treatment, and the patient's perception of their treatment is recognised as being an important outcome for clinical decision making [2]. In this letter we present the MCID of the SAQ using the anchor method.

110 patients were recruited from 6 UK specialist asthma centres who were starting a biologic treatment as part of usual care (62% female, mean age 49yrs, mean FEV1 67%). Participants completed the SAQ at baseline and completed the SAQ and a Global Rating of Change (GRoC) questionnaire [3] at 4, 8, 12 and 16 weeks after starting treatment. Patients responded to the 16 items of the SAQ using a 7-point scale, and responses were scored to produce an overall SAQ score from the mean of 16 items, and three subscale scores (My Life, My Mind, My Body) from the means of subsets of those 16 items [4]. In addition patients provided a single response to a

100-point Borg type rating of global quality of life, the SAQ-global. Questionnaires with >10% missing items were deemed invalid. Baseline mean (standard deviation) scores demonstrated significant HRQoL impairment across all aspects of the SAQ, 3.65 (1.49) for the SAQ, 3.74 (1.62) for My Life subscale, 3.78 (1.78) for My Mind subscale, 3.34 (1.51) for My Body subscale and 45.50 (23.67) for the SAQ-global. Questionnaire change scores were calculated by subtracting the baseline score from the follow up score, so that positive change scores indicated improvement in quality of life. There was a significant ($p < 0.01$) improvement between baseline and 4 weeks for the SAQ, the subscales of the SAQ and the SAQ-global, and improvement was maintained for subsequent weeks.

Patients were asked to rate the GRoC in terms of improvement by circling a statement 'which best describes how you feel since starting your new treatment for your asthma.' We analysed GRoC responses into any one of six categories: (1) any degree of deterioration, (2) 'no change,' (3) 'a little better,' (4) 'somewhat better' or 'moderately better,' (5) 'a good deal better,' and (6) 'a great deal better,' Perceived change of 'a little better' was defined as the point of the MCID following normal practice. In order to take full advantage of the repeated measures design, we used all available data where a GRoC rating was accompanied by a valid questionnaire change score over the 16 week study but excluded scores where the GRoC category was the repeat or deterioration of the previous week as such scores could be less reliable due to increased recall bias caused by the intervening experiences. The study received ethical approvals from the Research Ethics Committee/Health Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was sponsored by University Hospitals Plymouth NHS Trust.

The COVID pandemic reduced data collection at later time points. Of the 110 patients recruited 107 provided valid change scores at week 4, 74 at week 8, 30 at week 12 and 49 at week sixteen. Of the 28 judgements that were used to assess the MCID of the SAQ, 18 and 10 came from weeks 4 and 8 respectively. No additional judgements for MCID calculations were provided at weeks 12 or 16. The 110 patients recruited provided a total of 799 judgements that are presented in Table 1.

Table 4. Means, (n) and standard deviations of change scores for those reporting different degrees of global rating of change.

Description of change (GRoC scale number 0-5)	SAQ	SAQ My life	SAQ My mind	SAQ My body	SAQ-global
any degree of deterioration (-5 to -1)	-0.41 (4) 1.15	0.06 (4) 0.88	-1.23 (4) 1.45	-0.50 (4) 1.50	-5.00 (4) 15.81
no change (0)	-0.32 (34) 0.97	-0.30 (35) 1.04	-0.42 (35) 1.21	-0.25 (35) 1.32	0.95 (37) 16.78
'A little better' (1) (MCID)	0.54 (28) 0.94	0.67 (28) 0.90	0.43 (28) 1.11	0.45 (28) 1.38	10.89 (28) 14.91
'Somewhat better' and 'Moderately better' (2 or 3)	0.92 (34) 1.04	0.90 (33) 1.01	0.90 (33) 1.00	0.84 (33) 1.82	17.41 (34) 16.96
A good deal better' (4)	1.23 (33) 1.10	1.11 (33) 1.27	1.20 (33) 1.22	0.99 (33) 1.27	19.18 (33) 20.38
'A great deal better' (5)	2.19 (27) 1.05	2.19 (26) 1.19	2.32 (26) 1.52	2.15 (26) 1.70	31.83 (29) 19.00

These data show that the MCID for the SAQ is 0.5 and for the SAQ-global is 11. The MCID for the subscales of the SAQ are similar to that of the SAQ. Based on data

reported elsewhere [1] the standard error of measurement (SEM) [5] gives an MCID of 0.5 for the SAQ and 6.0 for the SAQ-global. The SEM method provides an estimate of statistical discrimination and should not normally be greater than that provided by the anchor method. An MCID of 0.5 is reported by the authors of another asthma questionnaire, the Asthma Quality of Life Questionnaire (AQLQ) [6] that, like the SAQ, asks patients to rate on a 7-point scale. However, the similarity in results should be interpreted cautiously as there are some differences in the anchor methodology, and the assessment of the MCID of the AQLQ was based on the mean of only 10 judgements. Other asthma questionnaires, such as the St George's respiratory questionnaire [7] have other forms of response format and are therefore not comparable.

In addition to providing the MCID for the SAQ, our data provide information about the multiples of the MCID that are equivalent to larger degrees of perceived change. A 'great deal better' is 4 times the MCID for the SAQ and 3 times the MCID for the SAQ-global. A 'good deal better' is 2 times the MCID for the SAQ and 2 times the MCID for the SAQ-global. These additional values can be used to assess the clinical significance of changes that are much greater than the MCID such as in super-responders.

The SAQ was developed with patients who contributed as partners to the content, wording and format of the questionnaire [8,9]. The 16 items are validated to be used as a single scale (SAQ) [1] or as three subscales (My Life, My Body, My Mind) [4], and the questionnaire also provides a global estimate of quality of life (SAQ-global). In this paper we have presented the MCID for all scoring methods.

References

1. Hyland ME, Jones RC, Lanario JW, Masoli M. The construction and validation of the Severe Asthma Questionnaire. *Eur Respir J*. 2018;52:1800618.
2. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *Journal of clinical epidemiology*. 2008;61(2):102-9.
3. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *Journal of Manual & Manipulative Therapy*. 2009;17(3):163-70.
4. Lanario JW, Hyland ME, Menzies-Gow A, Mansur AH, Dodd JW, Fowler SJ, et al. Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA). *Health and Quality of Life Outcomes*. 2020;18(1):1-10.
5. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. *Journal of evaluation in clinical practice*. 2000;6(1):39-49.
6. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. *Journal of clinical epidemiology*. 1994;47(1):81-7.
7. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. *Respiratory medicine*. 1991;85:25-31.
8. Hyland ME, Lanario JW, Pooler J, Masoli M, Jones RC. How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma. *Health and Quality of Life Outcomes*. 2018;16:1-9.

9. Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. *Qual Life Res.* 2015;24(3):631-9.